With years of experience producing cGMP viral vectors, we support a broad range of viral vector manufacturing platforms for gene and gene-modified cell therapies and vaccines including AAV, Adenovirus, Lentivirus, HSV, and Retrovirus. Our platforms are designed to support you from pre-clinical and human studies through to late phase and commercial programs.
Our capabilities include:
Pre-clinical | cGMP | Late-Phase Clinical & Commercial | |
---|---|---|---|
Suspension |
50L 200L |
50L 200L 4 x 200L 1000L |
50L 200L 4 x 200L 1000L 2000L |
Adherent |
Up to 48 flatstock vessels iCELLis® NANO iCELLis® 500 |
Up to 48 flatstock vessels iCELLis® 500 |
Up to 48 flatstock vessels iCELLis® 500 |
View video to learn about challenges and opportunities of bringing viral vector products to market
WatchLearn more about Patheon Viral Vector Services end-to-end capabilities.